← Research status explorer
Enhance / Reproductive & pigmentation
PT-141
Also known as: Bremelanotide, Vyleesi
Current research status
Approved Molecule*
Established pharmaceutical ingredient
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*
Overview
PT-141 (bremelanotide) is FDA-approved since June 2019, marketed as Vyleesi, for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. In clinical trials, roughly a quarter of Vyleesi-treated patients had a meaningful increase in desire score versus about 17% on placebo — a real but modest effect, not a guarantee of response, and specific to the approved product and indication.
Last reviewed: September 2026
*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.
